Abstract
Development and application of chimeric antigen receptor (CAR) T cell therapy has led to a breakthrough in the treatment of hematologic malignancies. In 2017, the FDA approved the first commercialized CD19-specific CAR T cell products for treatment of patients with B-cell malignancies. This success increased the desire to broaden the availability of CAR T cells to a larger patient cohort with hematological but also solid tumors. A critical factor of CAR T cell production is the stable and efficient delivery of the CAR transgene into T cells. This gene transfer is conventionally achieved by viral vectors. However, viral gene transfer is not conducive to affordable, scalable, and timely manufacturing of CAR T cell products. Thus, there is a necessity for developing alternative nonviral engineering platforms, which are more cost-effective, less complex to handle and which provide the scalability requirement for a globally available therapy.
One alternative method for engineering of T cells is the nonviral gene transfer by Sleeping Beauty (SB) transposition. Electroporation with two nucleic acids is sufficient to achieve stable CAR transfer into T cells. One of these vectors has to encode the gene of interest, which is the CAR , the second one a recombinase called SB transposase, the enzyme that catalyzes integration of the transgene into the host cell genome. As nucleic acids are easy to produce and handle SB gene transfer has the potential to provide scalability, cost-effectiveness, and feasibility for widespread use of CAR T cell therapies.
Nevertheless, the electroporation of two large-size plasmid vectors into T cells leads to high T cell toxicity and low gene transfer rates and has hindered the prevalent clinical application of the SB system. To circumvent these limitations, conventional plasmid vectors can be replaced by minimal-size vectors called minicircles (MC ). MCs are DNA vectors that lack the plasmid backbone, which is relevant for propagation in bacteria, but has no function in a human cell. Thus, their size is drastically reduced compared to conventional plasmids. It has been demonstrated that MC-mediated SB CAR transposition into T cells enhances their viability and gene transfer rate enabling the production of therapeutic doses of CAR T cells. These improvements make CAR SB transposition from MC vectors a promising alternative for engineering of clinical grade CAR T cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hay KA, Turtle CJ (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10(4):251–254
Salter AI, Pont MJ, Riddell SR (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131(24):2621–2629
Yakoub-Agha I, Chabannon C, Bader P et al (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105(2):297–316
Mestermann K, Giavridis T, Weber J et al (2019) The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med 11(499):eaau5907
Andrea AE, Chiron A, Bessoles S et al (2020) Engineering next-generation CAR T cells for better toxicity management. Int J Mol Sci 21(22):8620
Sommermeyer D, Hudecek M, Kosasih PL et al (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30(2):492–500
Turtle CJ, Hanafi LA, Berger C et al (2016) CD19 CAR T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123–2138
Parayath NN, Stephan SB, Koehne AL et al (2020) In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun 11(1):6080. https://doi.org/10.1038/s41467-020-19486-2
Ramos CA, Savoldo B, Dotti G (2014) CD19-CAR trials. Cancer J 20(2):112–118
Singh H, Manuri PR, Olivares S et al (2008) Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res 68(8):2961–2971
Singh H, Figliola MJ, Dawson MJ et al (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One 8(5):e64138
Field AC, Vink C, Gabriel R et al (2013) Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer. PLoS One 8(6):e68201
Kobelt D, Schleef M, Schmeer M et al (2013) Performance of high quality minicircle DNA for in vitro and in vivo gene transfer. Mol Biotechnol 53(1):80–89
Monjezi R, Miskey C, Gogishvili T et al (2017) Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors. Leukemia 31(1):186–194
Ivics Z, Hackett PB, Plasterk RH et al (1997) Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91(4):501–510
Izsvák Z, Ivics Z, Plasterk RH (2000) Sleeping beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 302:93–102
Mátés L, Chuah MK, Belay E et al (2009) Molecular evolution of a novel hyperactive sleeping beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41(6):753–761
Huang X, Guo H, Kang J et al (2008) Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 16(3):580–589
Peng PD, Cohen CJ, Yang S et al (2009) Efficient nonviral sleeping beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 8:1042–1049
Izsvák Z, Hackett PB, Cooper LJ et al (2010) Translating sleeping beauty transposition into cellular therapies: victories and challenges. BioEssays 32(9):756–767
Swierczek M, Izsvák Z, Ivics Z (2012) The sleeping beauty transposon system for clinical applications. Expert Opin Biol Ther 12(2):139–153
Clauss J, Obenaus M, Miskey C et al (2018) Efficient non-viral T-cell engineering by sleeping beauty Minicircles diminishing DNA toxicity and miRNAs silencing the endogenous T-cell receptors. Hum Gene Ther 29:569–584
Eberl L, Kristensen CS, Givskov M et al (1994) Analysis of the multimer resolution system encoded by the parCBA operon of broad-host-range plasmid RP4. Mol Microbiol 12(1):131–141
Smith MC, Thorpe HM (2002) Diversity in the serine recombinases. Mol Microbiol 44(2):299–307
Thomson JG, Ow DW (2006) Site-specific recombination systems for the genetic manipulation of eukaryotic genomes. Genesis 44(10):465–476
Jechlinger W, Azimpour Tabrizi T, Lubitz W et al (2004) Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol 8:222–231
Bigger BW, Tolmachov O, Collombet JM et al (2001) An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem 276(25):23018–23027
Chen ZY, He CY, Ehrhardt A et al (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8(3):495–500
Gossen JA, de Leeuw WJ, Molijn AC et al (1993) Plasmid rescue from transgenic mouse DNA using LacI repressor protein conjugated to magnetic beads. BioTechniques 14(4):624–629
Mayrhofer P, Blaesen M, Schleef M et al (2008) Minicircle-DNA production by site specific recombination and protein–DNA interaction chromatography. J Gene Med 10:1253–1269
Schmeer M, Schleef M (2014) Pharmaceutical grade large-scale plasmid DNA manufacturing process. Methods Mol Biol 1143:219–240
Schleef M, Schirmbeck R, Reiser M et al (2015) Minicircle: next generation DNA vectors for vaccination. Methods Mol Biol 1317:327–339
Chabot S, Orio J, Schmeer M et al (2013) Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery. Gene Ther 20(1):62–68
Hudecek M, Lupo-Stanghellini MT, Kosasih PL et al (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19(12):3153–3164
Hudecek M, Sommermeyer D, Kosasih PL et al (2015) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3(2):125–135
Brown CE, Wright CL, Naranjo A et al (2005) Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297(1–2):39–52
Sadelain M, Papapetrou EP, Bushman FD (2011) Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 12(1):51–58
Prommersberger S, Reiser M, Beckmann J et al (2021) CARAMBA: a first-in-human clinical trial with SLAMF7 CAR T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma. Gene Ther 28(9):560–571. https://doi.org/10.1038/s41434-021-00254-w
Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448
Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839–852
Kebriaei P, Singh H, Huls MH et al (2016) Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363–3376
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Prommersberger, S. et al. (2022). Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview. In: Walther, W. (eds) Gene Therapy of Cancer. Methods in Molecular Biology, vol 2521. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2441-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2441-8_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2440-1
Online ISBN: 978-1-0716-2441-8
eBook Packages: Springer Protocols